Developer / Researcher,Treatment vs. Vaccine,Product Category,Stage of Development,Anticipated Next Steps,Product Description,Clinical Trials for COVID-19,Funder,Published Results,Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only),FDA-Approved Indications,Sources,Date Last Updated
Roivant Sciences,Treatment,Antibodies,Clinical,Phase II study started in April 2020,"Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal",NCT04351243,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/14/2020
Generation Bio / Vir Biotechnology,Treatment,Antibodies,Pre-clinical,Unknown,Non-viral gene therapy to produce monoclonal antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Edesa Biotech / Light Chain Bioscience (NovImmune),Treatment,Antibodies,Pre-clinical,Unknown,"Monocloncal antibodies, TLR4 antagonist",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
University of Hong Kong (BMS),Treatment,Antibodies,Clinical,Phase II study not yet recruiting,"Opdivo (nivolumab), PD-1 blocking antibody","NCT04356508

NCT04333914 ",Unknown,,,"FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
Atreca / BeiGene / IGM Biosciences,Treatment,Antibodies,Pre-clinical,Unknown,"Novel IgM and IgA antibodies 
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Unknown,,,"N/A
",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Implicit Bioscience,Treatment,Antibodies,Clinical,Expanded access protocols,"IC14, recombinant chimeric anti-CD14 monoclonal antibody",NCT04346277,Unknown,,Acute Respiratory Distress Syndrome,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Numerous trials with Chinese research sponsors; Roche,Treatment,Antibodies,Clinical,Phase II/III studies recruiting April 2020,"Avastin (bevacizumab), vascular endothelial growth factor inhibitor","NCT04275414

NCT04305106

NCT04344782

",Unknown,,,"FDA-approved since 2004, approved to treat certain types of cancer",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
Numerous trials with Chinese research sponsors,Treatment,Antibodies,Clinical,Phase II study not yet recruiting,PD-1 blocking antibody; Thymosin,"NCT04268537        

ChiCTR2000030028 ",Unknown,,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
Centivax (Distributed Bio),Treatment,Antibodies,Pre-clinical,Unknown,Antibody,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
Tang-Du Hospital,Treatment,Antibodies,Clinical,Phase II/III recruiting April 2020,"meplazumab, anti-CD147 antibody",NCT04275245,Unknown,medRxiv (https://doi.org/10.1101/2020.03.21.20040691),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
Regeneron/ NIAID,Treatment,Antibodies,Clinical,Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase II stage of I/II/III treatment trial started July 2020,Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein,"NCT04425629, NCT04426695",Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
AstraZeneca; ACCORD trial ,Treatment,Antibodies,Clinical,ACCORD Phase II trial to start May 2020,"MEDI3506, monoclonal antibody targeting interleukin 33",,UK Government (ACCORD study),,Chronic Obstructive Pulmonary Diesase,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
Ligand Pharmaceuticals,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies (OmniChicken platform),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Kamada / Kedrion Biopharma,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie,Treatment,Antibodies,Pre-clinical,Unknown,Antibody 47D11,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Emergent BioSolutions / National Institute of Allergy and Infectious Diseases (NIAID),Treatment,Antibodies,Pre-clinical,Phase II trials begin ~August 2020,Polyclonal hyperimmune globulin (H-IG),,Biomedical Advanced Research and Development Authority (BARDA),,Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Eli Lilly / AbCellera (NIH Vaccines Research Center),Treatment,Antibodies,Clinical,Phase 1 started June 2020; results expected end of June 2020,LY-CoV555 antibody from recovered patients,,Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Chelsea and Westminster Hospital, Imperial College London",Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,UK Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
GSK,Treatment,Antibodies,Clinical,Phase II recruiting June 2020,"otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
",NCT04376684,Unknown,,"To treat rheumatoid arthritis
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/10/2020
Eli Lilly,Treatment,Antibodies,Clinical,Phase II to start in April 2020,"LY3127804, anti-Angiopoietin 2 (Ang2) antibody",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Edesa Biotech / Light Chain Bioscience (NovImmune),Treatment,Antibodies,Pre-clinical,Unknown,"Monocloncal antibodies, CXC10 antagonist",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
"CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)",Treatment,Antibodies,Pre-clinical,Phase I trials start in summer 2020; To patients between December 2020 and December 2021,"Polyclonal hyperimmune globulin (H-IG), unbranded",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital,Treatment,Antibodies,Clinical,Sharpy Memorial Hospital preliminary data released June 2020; Phase III trial to start May 2020,Octagam; intravenous Immunoglobulin (IVIG),"NCT04261426

NCT04264858

NCT04350580",Unknown,"Open Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740), (https://www.businesswire.com/news/home/20200603005130/en/Octapharma-USA-Extends-Funding-COVID-19-Study-Positive), medRxiv (https://doi.org/10.1101/2020.06.15.20132407)",,"FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
Abcore,Treatment,Antibodies,Pre-clinical,Unknown,"Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
Celltrion,Treatment,Antibodies,Pre-clinical,Unknown,Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Wuhan Jinyintan Hospital,Treatment,Antibodies,Clinical,"No trial updates since February 2020
","AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody",ChiCTR2000029806,Unknown,,Treatment of certain cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
University of Texas at Austin / US National Institutes of Health / Ghent University,Treatment,Antibodies,Pre-clinical,Unknown,Linked nanobody antibody,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/1/2020
Xbiotech / BioBridge Global,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Ligand Pharmaceuticals,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies (OmniRat platform),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
FairJourney Biologics / Iontas,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols),Treatment,Antibodies,Clinical,Phase II recruiting May 2020. Expanded access protocols,"Soliris (eculizumab), complement inhibitor","NCT04288713

NCT04346797

NCT04355494 ",Unknown,,,"FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
Celltrion,Treatment,Antibodies,Pre-clinical,Start Phase I in July 2020,"CT-P59; Antibodies from recovered COVID-19 patients
",,The Korea Health Industry Development Institute,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
Alexion Pharmaceuticals,Treatment,Antibodies,Clinical,Phase III to start in May 2020,"Ultomiris (ravulizumab-cwvz), complement inhibitor",NCT04369469,Unknown,,,"FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
GigaGen,Treatment,Antibodies,Pre-clinical,Unknown,"rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies",,Unknown,,,N//A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vir Biotechnology / GSK / Samsung / WuXi Biologics / Biogen,Treatment,Antibodies,Pre-clinical,Start Phase II ~July-September 2020,"VIR-7831 and VIR-7832, antibodies from recovered SARS patients",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2020
Swedish Orphan Biovitrum,Treatment,Antibodies,Clinical,Phase II/III recruiting April 2020,"Gamifant (emapalumab), anti-interferon gamma antibody",NCT04324021,Unknown,,,"FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
ImmunoPrecise Antibodies,Treatment,Antibodies,Pre-clinical,Unknown,Monoclonal antibody cocktail,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
CytoDyn,Treatment,Antibodies,Clinical,"Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020, interim results expected June/July 2020","leronlimab (PRO 140), a CCR5 antagonist","NCT04343651      

NCT04347239",Unknown,CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for),"Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
Grifols,Treatment,Antibodies,Pre-clinical,Unknown,Polyclonal hyperimmune globulin (H-IG),,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica",Treatment,Antibodies,Clinical,FDA approves Phase III trial in hospitalized patients in July 2020,"Sylvant (siltuximab), interleukin-6 targeted monoclonal","NCT04322188

NCT04330638

NCT04329650",Unknown,"EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/)       

medRxiv (https://doi.org/10.1101/2020.04.01.20048561)

medRxiv (https://doi.org/10.1101/2020.04.23.20076612)",,"FDA-approved since 2014, approved to treat multicentric Castleman disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
Vanderbilt Vaccine Center / AstraZeneca / IDBiologics,Treatment,Antibodies,Pre-clinical,Phase I trial begins in August 2020,Combo of two antibodies,,Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/15/2020
Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY,Treatment,Antibodies,Clinical,"Initial Roche studies could be completed May or June 2020; Phase II open label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020","Actemra (tocilizumab), interleukin-6 receptor antagonist","NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853",Biomedical Advanced Research and Development Authority (BARDA),"ChinaXiv (http://www.chinaxiv.org/abs/202003.00026), medRxiv (https://doi.org/10.1101/2020.04.20.20061861), medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid), PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1), medRxiv (https://doi.org/10.1101/2020.05.01.20078360), medRxiv (https://doi.org/10.1101/2020.05.07.20094599), medRxiv (https://doi.org/10.1101/2020.05.14.20099234), medRxiv (https://doi.org/10.1101/2020.05.13.20100404), medRxiv (https://doi.org/10.1101/2020.05.13.20100081), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.12.20122374), medRxiv (https://doi.org/10.1101/2020.06.08.20125245), medRxiv (https://doi.org/10.1101/2020.06.06.20122341), medRxiv (https://doi.org/10.1101/2020.06.05.20122622), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.06.05.20113738), medRxiv (https://doi.org/10.1101/2020.06.01.20119149), medRxiv (https://doi.org/10.1101/2020.05.29.20117358), medRxiv (https://doi.org/10.1101/2020.06.13.20130088), Italian Medicines Agency (https://www.aifa.gov.it/web/guest/-/covid-19-studio-randomizzato-italiano-nessun-beneficio-dal-tocilizumab), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), EClinicalMed (https://doi.org/10.1016/j.eclinm.2020.100418), Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30173-9), medRxiv (https://doi.org/10.1101/2020.06.23.20134072), medRxiv (https://doi.org/10.1101/2020.06.22.20133413), medRxiv (https://doi.org/10.1101/2020.06.24.20134288), The Lancet (https://doi.org/10.1016/j.eclinm.2020.100410)",,"FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis and cytokine release syndrome",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences,Treatment,Antibodies,Pre-clinical,Phase I trial begins Q3 2020,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial,Treatment,Antibodies,Clinical,"Phase III (US) results released July 2020 and US trial stopped, Phase III (ex-US in severe and critical hospitalized patients continues) results expected 3Q 2020","Kevzara (sarilumab), interleukin-6 receptor antagonist","NCT04315298, NCT04321993, NCT04341870, NCT04324073, NCT04327388, NCT04322773, NCT04345289, NCT02735707, NCT04357808, NCT04357860, NCT04359901",Biomedical Advanced Research and Development Authority (BARDA),"medRxiv (https://doi.org/10.1101/2020.04.23.20076612)Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive)ChinaXiv (http://www.chinaxiv.org/abs/202003.00026)medRxiv (https://doi.org/10.1101/2020.05.14.20094144), Regeneron (https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3)",,"FDA-approved since 2017, approved to treat rheumatoid
 arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
Public Health England (Stuart Dowall),Treatment,Antibodies,Pre-clinical,Unknown,Purified ovine immunoglobulin from immunized sheep,,UK Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Grifols,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Humanigen Inc.,Treatment,Antibodies,Clinical,Data on first clinical use released June 2020; Phase III trial recruiting June 2020,"lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody",NCT04351152,Unknown,"medRxiv (https://doi.org/10.1101/2020.06.08.20125369), (https://www.humanigen.com/press/Humanigen-Reports-Additional-Analysis-of-Lenzilumab-in-Severe-and-Critical-COVID-19-Patients)",Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Novartis; other research sponsors
",Treatment,Antibodies,Clinical,Novartis Phase III to start and trial top-line results expected late summer 2020,"Ilaris (canakinumab), interleukin-1beta blocker","NCT04348448

NCT04362813

NCT04365153",Unknown,The Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30167-3),,"FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Junshi Biosciences / Eli Lilly,Treatment,Antibodies,Clinical,Phase I trial in China started June 2020; trial in US to start 2H 2020   ,"JS016 antibody candidate
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Medicago / Laval University's Infectious Disease Research Centre,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Canadian Institutes for Health Research (CIHR),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
I-Mab Biopharma,Treatment,Antibodies,Clinical,"Interim Phase I/II data released June 2020, part 2 of the study to start June 2020","TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody",NCT04341116,Unknown,PR Newswire (https://www.prnewswire.com/news-releases/i-mab-reports-interim-results-from-part-1-study-for-anti-gm-csf-antibody-tjm2-to-treat-covid-19-patients-with--cytokine-release-syndrome-301066451.html),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Innovent Biologics,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sorrento Therapeutics / Mount Sinai Health System,Treatment,Antibodies,Pre-clinical,Start Phase II trial Q3 2020,COVI-SHIELD antibody cocktail that binds to three different epitopes,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2020
AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID) / University of Maryland School of Medicine,Treatment,Antibodies,Pre-clinical,Phase I trials begin in summer 2020,"Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Prellis Biologics,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
Emergent BioSolutions,Treatment,Antibodies,Pre-clinical,Phase II trials begin ~August 2020,Horse plasma product (COVID-EIG),,Unknown,,Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CSL Behring / SAb Biotherapeutics,Treatment,Antibodies,Pre-clinical,Phase I starts early summer 2020,"SAB-185, Polyclonal hyperimmune globulin (H-IG)",,Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"CSL Behring Australia
",Treatment,Antibodies,Pre-clinical,Unknown,"COVID-19 Immunoglobulin, plasma derived
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
Amgen / Adaptive Biotechnologies,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
InflaRx N.V.,Treatment,Antibodies,Clinical,Phase II topline results reported June 2020,"IFX-1, anti-C5a antibody",NCT04333420,Unknown,inflaRx (https://www.inflarx.de/Home/Investors/Press-Releases/06-2020-InflaRx-Reports-Encouraging-Topline-Results-from-the-Exploratory-Phase-II-Part-of-the-Adaptive-Randomized-Phase-II-III-Trial-of-IFX-1-in-COVID-19.html),"To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
"Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes; RECOVERY trial",Treatment,Antibodies,Clinical,"Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing",Convalescent plasma (blood plasma from recovered patients),"Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424",Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic),"medRxiv (https://doi.org/10.1101/2020.03.16.20036145), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983), medRxiv (https://doi.org/10.1101/2020.04.07.20056440), JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982), medRxiv (https://doi.org/10.1101/2020.05.08.20095471), medRxiv (https://doi.org/10.1101/2020.05.12.20099879), Amer J Pathology (https://ajp.amjpathol.org/article/S0002-9440(20)30257-1/fulltext), medRxiv (https://doi.org/10.1101/2020.05.20.20102236), JAMA (https://jamanetwork.com/journals/jama/article-abstract/2766943), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766940), (https://ctmirror.org/2020/05/17/cautious-enthusiasm-for-plasma-treatment-in-covid-19-cases/), (https://www.wbtv.com/2020/06/11/novant-health-physicians-say-convalescent-plasma-therapy-is-showing-promising-results-covid-fight/), medRxiv (https://doi.org/10.1101/2020.06.05.20122820), medRxiv (https://doi.org/10.1101/2020.05.26.20113373), medRxiv (https://doi.org/10.1101/2020.05.21.20109512), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.19.20135830), medRxiv (https://doi.org/10.1101/2020.06.21.20132944), Mayo Clinic Proceedings (https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft95_6_8.pdf), medRxiv (https://doi.org/10.1101/2020.06.24.20121905)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Cerecor,Treatment,Antibodies,Clinical,"Phase 2 to start in June 2020, top line data expected 4Q 2020","CERC-002, anti-LIGHT monoclonal antibody",,Unknown,,Pediatric Crohn's Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Celltrion,Treatment,Antibodies,Clinical,Phase II trial to start in June 2020,"Remsima (infliximab), anti-TNF antibody",,Unknown,,,"FDA-approved since 2016, approved to treat various autoimmune diseases",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Tychan/ SingHealth Investigational Medicine Unit,Treatment,Antibodies,Clinical,Phase I started June 2020; efficacy data expected 3Q 2020,"TY027, monoclonal antibody targeting SARS-CoV-2",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab,Treatment,Antibodies,Pre-clinical,,"IgY-110, anti-CoV-2 antibody (nasal spary application)",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Alliance
  - Proteona/ NMI/ NUS Enterprise/10X Genomics; NovogeneAIT/ Twist Bioscience/
  University Hospitals",Treatment,Antibodies,Pre-clinical,,Antibody for immunocompromised patients,,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Virna
  Therapeutics/ University of Toronto",Treatment,Antibodies,Pre-clinical,,Neutralizing antibodies,,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Kiniksa/
  Cleveland Clinic/ Ospedale San Raffaele",Treatment,Antibodies,Clinical,Phase II trial recruiting June 2020; Case reports published June 2020,"mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody","NCT04399980, NCT04397497",,Lancet (https://doi.org/10.1016/S2665-9913(20)30170-3),Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
Staidson/ Pivotal,Treatment,Antibodies,Clinical,Unknown,"BDB-100, monocloncal anti-C5a antibody",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
Tiziana Life Sciences,Treatment,Antibodies,Pre-clinical,Plan to initiate Phase 1 in Q1 2021,"TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
"SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV",Treatment,Antivirals,Pre-clinical,Unknown,Antiviral drug combinations,,EU Commission (Horizon 2020 Program),,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Beech Tree Labs
",Treatment,Antivirals,Clinical,"Has been used in 36 patients anecdotally","BTL-tml
",,Unknown,,"Treatment of herpes virus infections
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
BioCryst Pharmaceuticals,Treatment,Antivirals,Clinical,Phase Ib recruiting May 2020,galidesivir,NCT03891420,National Institute of Allergy and Infectious Diseases (NIAID),,Treatment of yellow fever,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS),Treatment,Antivirals,Clinical,Phase II/III to start in Q3 2020,"emetine hydrochloride
",,Unknown,,"To treat viral hepatitis and varicella-virus
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
Ansun Biopharma / Renmin Hospital of Wuhan University,Treatment,Antivirals,Clinical,Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020,"DAS181, recombinant sialidase (nebulized)
","NCT03808922

NCT04354389

NCT04298060

NCT04324489",Unknown,PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html),Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
"Fujifilm Toyama Chemical / Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors / Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School / Glenmark Pharmaceuticals",Treatment,Antivirals,Clinical,Fuijfilm trial to continue into July 2020; Phase III trial in India started May 2020 with results expected by July/August 2020 (Glenmark),"Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza","NCT04303299

NCT04310228

ChiCTR2000029548

ChiCTR2000029496

ChiCTR2000029544         

ChiCTR2000030254

NCT04336904

NCT04333589

NCT04345419",Life Arc (FLARE trial; PIONEER trial),"medRxiv (https://doi.org/10.1101/2020.03.17.20037432), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html), Critical Care (https://doi.org/10.1186/s13054-020-03078-z)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
ViralClear Pharmaceuticals,Treatment,Antivirals,Pre-clinical,Unknown,"Vicromax, broad spectrum antiviral",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ISR Immune System Regulation,Treatment,Antivirals,Pre-clinical,Unknown,ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Bukwang Pharm,Treatment,Antivirals,Clinical,Phase II trial not yet recruiting,Levovir (clevudine),NCT04347915,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Agastiya Biotech,Treatment,Antivirals,Pre-clinical,Phase I to start in 2020,AB001,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Cocrystal Pharma,Treatment,Antivirals,Pre-clinical,Unknown,Antiviral compounds,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck,Treatment,Antivirals,Clinical,Phase II trial started June 2020,"EIDD-2801, oral ribonucleoside analog","NCT04405739, NCT04405570, NCT04392219",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Ascletis / Chinese research sponsors,Treatment,Antivirals,Clinical,Phase III trial recruiting May 2020,"ASC09, HIV protease inhibitor","NCT04261907

NCT04261270",Unknown,,Treatment of HIV/AIDS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Roche; REMAP-CAP global trial,Treatment,Antivirals,Clinical,"REMAP-CAP trial recruiting May 2020
","Tamiflu (oseltamivir), neuraminidase inhibitor","NCT04303299

NCT04255017        

NCT04261270

NCT02735707

NCT04338698

NCT04371601",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.28.20045955)       

medRxiv (https://doi.org/10.1101/2020.04.11.20056523)",,"FDA-approved since 1999, approved to treat and prevent influenza",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
"Plan Nacional sobre el Sida
",Treatment,Antivirals,Clinical,Phase III trial recruiting May 2020,"Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)","ChiCTR2000029468

NCT04334928",Unknown,,,"FDA-approved since 2004, approved to treat and prevent HIV-1 infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Bausch Health,Treatment,Antivirals,Clinical,Phase II recruiting May 2020; Individual patient expanded access,Virazole (ribavirin for inhalation solution),NCT04356677,Unknown,,,"FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Atea Pharmaceuticals,Treatment,Antivirals,Clinical,Phase II trial to start May 2020,"AT-527, oral purine nucleotide prodrug",NCT04396106,Unknown,,Treatment of Hepatitis C infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
Ascletis / Chinese research sponsors,Treatment,Antivirals,Clinical,Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020,"Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C","NCT04291729

NCT04345276",Unknown,medRxiv (https://doi.org/10.1101/2020.03.22.20034041),"Treatment of Hepatitis C
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Cidara Therapeutics,Treatment,Antivirals,Pre-clinical,Unknown,antiviral Fc conjugates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes,Treatment,Antivirals,Clinical,"EU grants conditional authorization July 3, 2020; Gilead starting Phase I of inhalant version in June 2020; Gilead starting Phase II/III trial in pediatric patients in June 2020; FDA issued an Emergency Use Authorization on May 1, 2020; Expanded access protocols","remdesivir, nucleotide analog","NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579",Unknown,"NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191), Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/), Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326), Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational), NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=), Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9), medRxiv (https://doi.org/10.1101/2020.05.02.20088559), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home), Gilead (https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), medRxiv (https://doi.org/10.1101/2020.05.17.20104711), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.26.20109595), medRxiv (https://doi.org/10.1101/2020.05.23.20110932), medRxiv (https://doi.org/10.1101/2020.06.15.20131227), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.22.20136531)",Treatment of Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
"Multiple global research sponsors
",Treatment,Antivirals,Clinical,Phase IV trials recruiting May 2020,"Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections","NCT04252885

NCT04350684 

NCT04286503

NCT04260594

NCT04273763",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.19.20038984)       Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)     medRxiv (https://doi.org/10.1101/2020.03.17.20037432)       medRxiv (https://doi.org/10.1101/2020.03.28.20045955)       medRxiv (https://doi.org/10.1101/2020.04.08.20057539)        medRxiv (https://doi.org/10.1101/2020.04.06.20042580)       medRxiv (https://doi.org/10.1101/2020.04.11.20056523)medRxiv (https://doi.org/10.1101/2020.04.25.20079079), medRxiv (https://doi.org/10.1101/2020.06.09.20076646), medRxiv (https://doi.org/10.1101/2020.05.30.20117598)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/16/2020
"Multiple global research sponsors
",Treatment,Antivirals,Clinical,Phase III trials recruiting May 2020,"Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)","ChiCTR2000029541 

NCT04252274

NCT04303299

NCT04304053",Unknown,,,"FDA-approved since 2015, approved to treat HIV-1 infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2020
Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial,Treatment,Antivirals,Clinical,WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm,"Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor","NCT04303299

NCT04255017

ChiCTR2000029548

ChiCTR2000029539

EudraCT 2020-000936-23

NCT04307693

NCT04315948

NCT04252885

NCT04276688

NCT02735707

NCT04321993

2020-001113-21

NCT04286503

NCT04328012

NCT04346147",UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial),"NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true)medRxiv (https://doi.org/10.1101/2020.03.19.20038984)Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)medRxiv (https://doi.org/10.1101/2020.03.28.20045955)medRxiv (https://doi.org/10.1101/2020.04.08.20057539)medRxiv (https://doi.org/10.1101/2020.04.21.20066761)medRxiv (https://doi.org/10.1101/2020.04.25.20079079)medRxiv (https://doi.org/10.1101/2020.04.24.20077735)The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext) medRxiv (https://doi.org/10.1101/2020.05.13.20094193), medRxiv (https://doi.org/10.1101/2020.05.18.20105650), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.05.27.20114470), medRxiv (https://doi.org/10.1101/2020.06.16.20133298), Recovery Trial press release (https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19)",,"FDA-approved since 2000, approved to treat HIV-1 infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
"Stanford
  University/ US Department of Energy's Lawrence Berkeley National Laboratory",Treatment,Antivirals,Pre-clinical,Unknown,Prophylactic antiviral CRISPR in human cells (PAC-MAN),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
"Anivive
  Lifesciences",Treatment,Antivirals,Pre-clinical,,"GC376, protease inhibitor",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Lattice Biologics,Treatment,Cell-based therapies,Clinical,Phase I enrolling April 2020,"AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Naturecell,Treatment,Cell-based therapies,Clinical,Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020,"Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
ImmunityBio / NantKwest / Be The Match BioTherapies,Treatment,Cell-based therapies,Pre-clinical,Phase Ib trial to start June 2020,Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Numerous trials with global research sponsors,Treatment,Cell-based therapies,Clinical,Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020,Mesenchymal stem cells,"30 trials listed in clinicaltrials.gov

ChiCTR2000029990

NCT04315987

NCT04302519

NCT04288102

NCT04313322

NCT04273646

NCT04371601

NCT04315987

NCT04252118

NCT04336254

NCT04339660

NCT04371601

NCT04366063",Unknown,"Aging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml)       

ChinaXiv (http://chinaxiv.org/abs/202002.00084)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
Hope Biosciences,Treatment,Cell-based therapies,Clinical,Phase II started in April 2020,"Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)","NCT04348435

NCT04349631

NCT04362189",Hope Biosciences Stem Cell Research Foundation,,Rheumatoid arthritis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
ImmunityBio / NantKwest,Treatment,Cell-based therapies,Pre-clinical,Pre-IND submitted to FDA in May 2020,"haNK, natural killer cells",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Mesoblast/ Cardiothoracic Surgical Trials Network,Treatment,Cell-based therapies,Clinical,Individual patient expanded access; Expanded access protocols; Individual patient expanded access data shared April 2020; Phase III trial recruiting May 2020,"Ryoncil (remestemcel-L), allogenic mesenchymal stem cells","NCT04366830

NCT04371393",Unknown,Mesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460),"Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Athersys / The University of Texas Health Science Center at Houston,Treatment,Cell-based therapies,Clinical,Phase II/III trial recruiting May 2020,"MultiStem, bone marrow stem cells",NCT04367077,Medical Technology Enterprise Consortium (MTEC),,Acute Respiratory Distress Syndrome; Stroke,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
AlloVir / Baylor College of Medicine,Treatment,Cell-based therapies,Pre-clinical,Unknown,Allogeneic T-cell therapies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Celltex,Treatment,Cell-based therapies,Clinical,"FDA approves Phase II trial on June 26, 2020",Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs),NCT04428801,Unknown,"Celltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/)

Celltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/)","Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Celularity/ Lung Biotechnology PBC,Treatment,Cell-based therapies,Clinical,Phase I/II study not yet recruiting May 2020,"CYNK-001, allogeneic, natural killer cell therapy",NCT04365101,Unknown,,Various hematologic cancers and solid tumors,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Capricor Inc.,Treatment,Cell-based therapies,Clinical,Expanded access protocol trial ongoing May 2020,"CAP-1002, allogenic cardiosphere-derived cells",NCT04338347,Unknown,,Duchenne muscular dystrophy,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Pluristem Therapeutics/BIH Center for Regenerative Therapy / Berlin Center for Advanced Therapies,Treatment,Cell-based therapies,Clinical,Results from individual patient expanded access released in April 2020,"PLX cell product, placenta-based cell therapy",,Unknown,Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf),"Various conditions
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
Duke-NUS Medical School,Treatment,Cell-based therapies,Pre-clinical,Unknown,Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2020
GC LabCell / KLEO Pharmaceuticals,Treatment,Cell-based therapies,Pre-clinical,Begin Phase I by end of 2020,Natural killer cell-based therapy,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
SMSbiotech,Treatment,Cell-based therapies,Pre-clinical,Unknown,Small mobile stem (SMS) cells,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
"AgeX
  Therapeutics/ ImStem Biotechnology",Treatment,Cell-based therapies,Pre-clinical,,"IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Sirnaomics,Treatment,RNA-based treatments,Pre-clinical,Unknown,RNAi - testing 150 RNAis,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vir Biotech / Alnylam Pharmaceuticals,Treatment,RNA-based treatments,Pre-clinical,Phase I to start by the end of 2020,VIR-2703 (ALN-COV) siRNA candidate,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
Mateon Therapeutics,Treatment,RNA-based treatments,Clinical,"Phase II study IND submitted to FDA on April 27, 2020","OT-101, a TGF-Beta antisense drug candidate",,Unknown,,Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Neurimmune / Ethris,Treatment,RNA-based treatments,Pre-clinical,Phase I to start Q4 2020,Inhaled mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID),Treatment,RNA-based treatments,Pre-clinical,Unknown,"Antisense oligonucleotides, peptide conjugated",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/1/2020
AIM ImmunoTech / National Institute of Infectious Diseases in Japan,Treatment,RNA-based treatments,Pre-clinical,Unknown,Ampligen; (rintatolimod),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
COVID-19 Therapeutics Accelerator,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compound libraries,,Gates Foundation / Wellcome / Mastercard Impact Fund,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/1/2020
Vir Biotechnology / GSK,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify anti-coronavirus compounds that target cellular host genes,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2020
Southwest Research Institute,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening drug compounds,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Janssen Pharmaceutical Companies,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning library of antiviral compounds,,Biomedical Advanced Research and Development Authority (BARDA),,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Anixa Biosciences / OntoChem,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening for antiviral drug candidates,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
Vanda Pharmaceuticals / University of Illinois at Chicago,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening of drug compounds,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2020
Queens University Belfast,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,UK Government,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Healx,Treatment,Scanning compounds to repurpose,Pre-clinical,Combinations will be ready for pre-clinical testing in May 2020,Artificial intellegence-based screening to identify repurposed drug combinations,,Unknown,,N/A,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Materia Medica / Cyclica,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Repurposing antiviral drug candidates,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Takeda,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Enanta Pharmaceuticals,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening new drugs + library of antiviral compounds,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Shionogi / Hokkaido University Research Center for Zoonosis Control,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify novel drugs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2020
Nuritas,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,AI-based screening to identify a peptide cocktail,,Partnership for Advanced Computing in Europe (PACE),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Pfizer,Treatment,Scanning compounds to repurpose,Pre-clinical,Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020,Scanning antiviral compounds previously in development,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Novartis,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA",Treatment,Scanning compounds to repurpose,Pre-clinical,Identified 30 known drugs that inhibit SARS-CoV-2 replication,Identifying drugs to repurpose,,Unknown,bioRxiv (https://doi.org/10.1101/2020.04.16.044016),,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identifying drugs to repurpose,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Merck,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Southwest
  Research Institute/ US Department of Defense (DOD)",Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening drug compounds,,The Henry M. Jackson Foundation for the Advancement of Military Medicine,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Wyss
  Institute",Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify FDA-approved drugs to repurpose to prevent or treat COVID-19,,US Defense Advanced Research Projects Agency (DARPA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Exscalate4Cov,
  public-private consortium",Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening a chemical library of 500 billion molecules,,European Commision's Horizon 2020,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
Quantitative Biosciences Institute Coronavirus Research Group,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Reviewing existing drugs and compounds through mapping viral-human protein interactions,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
Bioxytran,Treatment,Other,Pre-clinical,Unknown,BXT-25; glycoprotein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust),Treatment,Other,Clinical,Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start July 2020,"EDP1815, oral single strain of microbe ",NCT04393246,Unknown,,Psoriasis and Atopic Dermatitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors,Treatment,Other,Clinical,Unknown,ivermectin,"NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884",Unknown,medRxiv (https://doi.org/10.1101/2020.06.06.20124461),,"FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health,Treatment,Other,Clinical,Phase III trial started in April 2020,"tradipitant, a neurokinin-1 receptor antagonist",NCT04326426,Unknown,,"Gastroparesis, motion sickness, and atopic dermatitis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2020
Can-Fite BioPharma,Treatment,Other,Clinical,IND (investigational new drug application) expected to be filed with FDA by end of June 2020,"piclidenoson, A3 adenosine receptor agonist",NCT04333472,Unknown,,Rheumatoid arthritis; psoriasis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center,Treatment,Other,Clinical,Unknown,"Ryanodex (dantrolene sodium), skeletal muscle relaxant",,Unknown,,,"FDA-approved since 2014, approved to prevent and treat malignant hyperthermia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
"Novartis / Incyte, numerous researchers globally",Treatment,Other,Clinical,Novartis/Incyte Phase III trial started April 2020; Expanded access protocols,Jakafi/jakavi (ruxolitinib),"ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098, NCT04403243",LIfeArc (RAVEN trial),J. Allergy & Clinical Immuno. (https://www.jacionline.org/article/S0091-6749(20)30738-7/abstract),,"FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/25/2020
Romark Laboratories; various researchers globally,Treatment,Other,Clinical,Unknown,"nitazoxanide, antiprotozoal","NCT04351347

NCT04348409

NCT04343248

NCT04341493

NCT04345419",Unknown,,,"FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
CEL-SCI / University of Georgia Center for Vaccines and Immunology,Treatment,Other,Pre-clinical,Unknown,Peptides targeting the NP protein,,Unknown,,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Zydus Cadila Group; The Camelot Foundation
",Treatment,Other,Clinical,Phase II/III enrolling May 2020,"interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep 
","NCT04273763

NCT04349410",Unknown,medRxiv (https://doi.org/10.1101/2020.05.29.20109199),,"PegIntron - FDA-approved since 2001, approved to treat hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat hepatitis C and certain cancers",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/16/2020
Cyclacel Pharmaceuticals / University of Edinburgh,Treatment,Other,Clinical,Unknown,"roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor",,LifeArc,,Rheumatoid arthritis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
aTyr,Treatment,Other,Clinical,Phase II study started in June 2020,"ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2",NCT04412668,Unknown,,Pulmonary sarcoidosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent",Treatment,Other,Clinical,Phase II and Phase IV trials recruiting July 2020,"Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )","NCT04326920, NCT04400929",Unknown,,Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine),"FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Aldeyra Therapeutics,Treatment,Other,Clinical,IND submission to FDA in Q3 2020,"ADX-1612, HSP 90 inhibitor",,Unknown,,Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
"Chimerix
",Treatment,Other,Clinical,Phase II/III trial recruiting July 2020,"DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin
",NCT04389840,Unknown,,"Acute myeloid leukemia
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Biomarck Pharmaceuticals,Treatment,Other,Clinical,Unknown,"BIO-11006, inhaled peptide",,Unknown,,Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Shanghai Jiao Tong University School of Medicine,Treatment,Other,Clinical,Phase III trial recruiting May 2020,Recombinant human interferon alpha-1b,NCT04320238,Unknown,medRxiv (https://doi.org/10.1101/2020.04.11.20061473),,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
"SciTech Development, LLC",Treatment,Other,Clinical,Unknown,"ST-001 nanoFenretinide (fenretinide)
",,Unknown,,non-Hodgkin's lymphoma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London",Treatment,Other,Clinical,Phase II trial recruiting; Individual patient expanded access,"Activase (alteplase), tissue plasminogen activator (tPA)","NCT04357730, NCT04356833",Unknown,,,"FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Multiple global research sponsors, including UK SPIKE-1 trial",Treatment,Other,Clinical,"Phase I/II, Phase II, and Phase III trials recruiting in May 2020","camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis","NCT04321096

NCT04353284

NCT04338906

NCT04374019

NCT04355052",LIfeArc (SPIKE-1 trial),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development; Bellerophon Pulse Technologies,Treatment,Other,Clinical,Mass. General Hopsital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020,Nitric oxide,"NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828",Unknown,,,"FDA-approved since 1999, approved to improve oxygenation in neonates",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Multiple global research sponsors
",Treatment,Other,Clinical,"Phase II, Phase II/III, and Phase IV trials recruiting in May 2020","Cozaar (losartan), angiotensin II receptor blocker (ARB)
","NCT04312009

NCT04311177

NCT04349410

NCT04335123

NCT04343001

NCT04328012

NCT04340557","COVID-19 Treatment Accelerator 
",,,"FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
Amgen,Treatment,Other,Clinical,Unknown,"Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)",,Unknown,,,"FDA-approved since 2014, approved to treat psoriatic arthritis, severe plaque psoriasis, and oral ulcers associated with Behcet's Disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Immunic, Inc.",Treatment,Other,Clinical,"Phase II trial started June 2020, top line results expected in 2020","IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor",,Unknown,,Ulcerative colitis; remitting multiple sclerosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Numerous research sponsors globally,Treatment,Other,Clinical,Open label Greek study results published June 2020,colchicine,"NCT04326790, NCT04328480, NCT04322565, NCT04322682, NCT04392141, NCT04375202, NCT04355143, NCT04360980, NCT04350320, NCT04416334, NCT04403243, NCT04363437, NCT04324463, NCT04367168",Unknown,JAMA Network Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593),,"N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/25/2020
Innovation Pharmaceuticals,Treatment,Other,Clinical,Unknown,"Brilacidin, a defensin mimetic",,Unknown,,Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Arch Biopartners,Treatment,Other,Clinical,FDA and Health Canada approved Phase II trial start in June 2020,"Metablok (LSALT peptide), selective dipeptidase-1 antagonist",NCT04402957,Unknown,,Lung and Kidney Inflammation,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)",Treatment,Other,Clinical,University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation,"nafamostat, approved in Japan to treat pancreatitis and other diseases","NCT04352400, NCT04418128",Unknown,Critical Care (https://doi.org/10.1186/s13054-020-03078-z),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
OncoImmune,Treatment,Other,Clinical,Phase III trial progress report released in June 2020,"CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)",NCT04317040,Unknown,(https://www.businesswire.com/news/home/20200614005028/en/OncoImmune-Reports-Progress-Phase-III-Clinical-Trial),Graft versus Host Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain,Treatment,Other,Clinical,Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020,"Aplidin (plitidepsin), approved in Australia to treat multiple myeloma",NCT04382066,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Cyclacel Pharmaceuticals / University of Edinburgh,Treatment,Other,Clinical,Unknown,"fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor",,LifeArc,,Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital,Treatment,Other,Clinical,FDA grants Fast Track Designation June 2020; Phase II/III trial started in April 2020; Expanded access protocols,"Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)","NCT04311697, NCT04453839, NCT04360096",Unknown,,"Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Apeptico,Treatment,Other,Clinical,Unknown,solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha),,EU Commission (Horizon 2020 Program),,"Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Panoptes Pharma GmbH,Treatment,Other,Clinical,Unknown,PP-001,,Unknown,,Severe eye diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
4D Pharma,Treatment,Other,Clinical,Phase II enrolling July 2020,"MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human","NCT04363372, EudraCT 2020-001597-30",Unknown,,Asthma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University,Treatment,Other,Clinical,Trial starts April 2020,ARMS-1,,Cleveland Foundation,,Influenza prophylaxis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Blade Therapeutics,Treatment,Other,Clinical,Unknown,"BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9",NCT04334460,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Laurent Pharmaceuticals,Treatment,Other,Clinical,Phase II trial recruiting July 2020,LAU-7b (fenretinide),NCT04417257,Unknown,,Treat exaggerated inflammatory response in adult cystic fibrosis patients,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
ImmunityBio / NantKwest,Treatment,Other,Clinical,Phase Ib trial to start June 2020,"N-803, IL-15 ""superagonist"" (Nogapendekin alfa inbakicept)",NCT04385849,Unknown,,Bladder Carcinoma In Situ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Institut National de la Sante et de la Recherche Medicale (Merck KGaA),Treatment,Other,Clinical,Phase III trial recruiting May 2020,Rebif (interferon beta-1a),"EudraCT 2020-000936-23     

NCT04315948",Unknown,,,"FDA-approved since 2002, approved to treat multiple sclerosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Chelation Partners,Treatment,Other,Pre-clinical,Unknown,"DIBI, iron-binding polymer",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
KD Pharma / SLA Pharma,Treatment,Other,Clinical,Unknown,"EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules",,Unknown,,Familial adenomatous polyposis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"MediciNova/ Yale
",Treatment,Other,Clinical,Phase II trial FDA approved and not yet recruiting July 2020  ,"MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor",NCT04429555,Unknown,,"Treatment of numerous neurodegenerative diseases and substance dependence
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Aldeyra Therapeutics,Treatment,Other,Clinical,IND submission to FDA in June 2020,"ADX-629, orally available reactive aldehyde species (RASP) inhibitor",,Unknown,,Systemic immune-mediated diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
"AstraZeneca; ACCORD study 
",Treatment,Other,Clinical,Case series results released June 2020; ACCORD Phase II trial to start May 2020,"Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor","NCT04346199

NCT04380688","UK Government (ACCORD study)
",Science Immunology (https://immunology.sciencemag.org/content/5/48/eabd0110),,"FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
CalciMedica,Treatment,Other,Clinical,Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020,"Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibtor",NCT04345614,Unknown,CalciMedica (https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia),Pancreatitis,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Pneumagen Ltd.,Treatment,Other,Pre-clinical,Unknown,"Neumifil, multivalent carbohydrate binding molecules",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Multiple global research sponsors
",Treatment,Other,Clinical,Phase IV trials recruiting May 2020,"Diovan (valsartan), angiotensin II receptor blocker (ARB)","NCT04335786

NCT04330300",Unknown,,,"FDA-approved since 1996, approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
"RedHill Biopharma
",Treatment,Other,Clinical,Preliminary data from individual patient expanded access released in April 2020,"Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor
","NCT04435106, NCT04414618",Unknown,"RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15258), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15257), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261), medRxiv (https://doi.org/10.1101/2020.06.20.20099010)","Various oncology indications
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/25/2020
Moleculin Biotech / University of Texas Medical Branch,Treatment,Other,Pre-clinical,Unknown,"WP1122, glucose decoy prodrug (and related drug candidates)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Swedish Orphan Biovitrum / REMAP-CAP global trial,Treatment,Other,Clinical,Unknown,"Kineret (anakinra), interleukin-1 receptor antagonist","NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881",Unknown,"medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Lancet (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext), medRxiv (https://doi.org/10.1101/2020.06.15.20132407)",,"FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Persephone Biosciences,Treatment,Other,Pre-clinical,Clinical trials to start in 2020,Microbiome therapeutic,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2020
Silkim Pharma,Treatment,Other,Pre-clinical,Unknown,"Coronzot, a novel family of drugs, sequestration of the labile iron",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/1/2020
BerGenBio; ACCORD study,Treatment,Other,Clinical,"ACCORD trial started June 2020, top line data expected summer 2020 ","bemcentinib, selective AXL kinase inhibitor",,UK Government (ACCORD study),,Various cancers ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
NanoViricides/ TheraCour Pharma Inc.,Treatment,Other,Pre-clinical,Unknown,A number of synthesized nanoviricide drug candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial",Treatment,Other,Clinical,"Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped; Univ. of Minnesota trial results released June 2020 ","Chloroquine/ Hydroxychloroquine, antimalarial","Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147",COVID-19 Treatment Accelerator (University of Washington/NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial),"NCT04261517 (https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29), IHU-Méditerranée Infection (https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf), Journal of ZheJiang University (Medical Sciences) (http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03), medRxiv (https://doi.org/10.1101/2020.03.22.20040758), Int'l Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2020.105949), medRxiv (ChiCTR2000029559) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.03.22.20040949), medRxiv (https://doi.org/10.1101/2020.04.02.20047050), medRxiv (https://doi.org/10.1101/2020.03.31.20048777), medRxiv (https://doi.org/10.1101/2020.03.24.20042366), medRxiv (NCT04323527) (https://doi.org/10.1101/2020.04.07.20056424), medRxiv (https://doi.org/10.1101/2020.04.08.20057539), medRxiv (https://doi.org/10.1101/2020.04.08.20054551), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub), ISAC (https://www.isac.world/news-and-publications/official-isac-statement), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0924857920300996), medRxiv (https://doi.org/10.1101/2020.04.10.20060699), medRxiv (ChiCTR2000029868) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.04.14.20065276), medRxiv (https://doi.org/10.1101/2020.04.16.20065920), medRxiv (https://doi.org/10.1101/2020.04.16.20068205), medRxiv (https://doi.org/10.1101/2020.04.22.20075671), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), medRxiv (https://doi.org/10.1101/2020.04.26.20081059), medRxiv (https://doi.org/10.1101/2020.04.27.20082180), medRxiv (https://doi.org/10.1101/2020.04.27.20073379), medRxiv (https://doi.org/10.1101/2020.04.27.20074583), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2012410), medRxiv (https://doi.org/10.1101/2020.05.02.20080036), medRxiv (https://doi.org/10.1101/2020.05.02.20088872), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766117), medRxiv (https://doi.org/10.1101/2020.05.07.20093831), medRxiv (https://doi.org/10.1101/2020.05.07.20094326), medRxiv (https://doi.org/10.1101/2020.05.05.20088757), BMJ (https://www.bmj.com/content/369/bmj.m1849), BMJ (https://www.bmj.com/content/369/bmj.m1844), medRxiv (https://doi.org/10.1101/2020.05.14.20101774), medRxiv (https://doi.org/10.1101/2020.05.12.20099028), medRxiv (https://doi.org/10.1101/2020.05.13.20094193), The Lancet (retracted) (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext), Lancet correction (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31249-6/fulltext), Lancet concern (https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)31290-3/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2016638), Lancet retraction (https://www.thelancet.com/lancet/article/s0140673620313246), medRxiv (https://doi.org/10.1101/2020.05.18.20066902), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.11.20126359), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.06.05.20122705), medRxiv (https://doi.org/10.1101/2020.06.09.20116806), medRxiv (https://doi.org/10.1101/2020.06.10.20101105), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.27.20114066), medRxiv (https://doi.org/10.1101/2020.05.28.20114835), medRxiv (https://doi.org/10.1101/2020.06.01.20118901), medRxiv (https://doi.org/10.1101/2020.05.28.20115741), medRxiv (https://doi.org/10.1101/2020.05.19.20106906), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.16.20132597), medRxiv (https://doi.org/10.1101/2020.06.17.20133884), medRxiv (https://doi.org/10.1101/2020.06.16.20133066), medRxiv (https://doi.org/10.1101/2020.06.16.20132878), J of Critical Care (https://doi.org/10.1016/j.jcrc.2020.03.005), medRxiv (https://doi.org/10.1101/2020.06.19.20136093), medRxiv (https://doi.org/10.1101/2020.06.19.20135475), medRxiv (https://doi.org/10.1101/2020.06.23.20137992), medRxiv (https://doi.org/10.1101/2020.06.26.20056507), medRxiv (https://doi.org/10.1101/2020.06.24.20139386), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19), It'l J Infectious Disease (ttps://doi.org/10.1016/j.ijid.2020.06.099)",,"FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Aarhus University,Treatment,Other,Clinical,Phase II trial ongoing July 2020,senicapoc,EudraCT 2020-001420-34,The Danish Government,,Sickle cell anemia; Alzheimer's disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Biohaven/ Thomas Jefferson University,Treatment,Other,Clinical,Phase II/III recruiting July 2020,"vazegepant, CGRP receptor antagonist",NCT04346615,Unknown,,Acute migraine,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
University of British Columbia/Apeiron Biologics,Treatment,Other,Clinical,Phase II began in April 2020,APN01; recombinant soluble human Angiotensin Converting Enzyme 2,,Austrian Government,,"Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Quotient Sciences/ CytoAgents,Treatment,Other,Pre-clinical,Phase I/II to start in 2020,"GP1681, small molecule inhibitor of cytokine release",,Richard King Mellon Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Noveome Biotherapeutics/ Singota Solutions,Treatment,Other,Clinical,Phase I/II to start in Q4 2020,"ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells",,Commonwealth of Pennsylvania,,Multiple ophthalmic indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
BioAegis Therapeutics Inc.,Treatment,Other,Clinical,Phase II trial not yet recruiting July 2020,recombinant human plasma gelsolin (rhu-pGSN),NCT04358406,Unknown,,Community-acquired pneumonia,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
CTI Biopharma,Treatment,Other,Clinical,"Phase III trial recruiting July 2020, results expected by the end of 2020","pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR",NCT04404361,Unknown,,Myelofibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Pharming,Treatment,Other,Clinical,Phase II trial not yet recruiting July 2020; compassionate use,Ruconest (recombinant human C1 esterase inhibitor),NCT04414631,Unknown,Pharming (https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf),,"FDA-approved since 2014, approved to treat hereditary angioedema",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Algernon Pharmaceuticals,Treatment,Other,Pre-clinical,Unknown,"Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB",,Unknown,,Idiopathic Pulmonary Fibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Eiger BioPharmaceuticals, Inc.",Treatment,Other,Clinical,Phase II began in April 2020,Peginterferon lambda,NCT04331899,Unknown,,Hepatitis Delta,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Feinstein Institutes for Medical Research at Northwell Health/ Alchem,Treatment,Other,Clinical,Phase II study underway in April 2020,"Pepcid (famotidine), histamine-2 (H2) receptor antagonist","NCT04389567, NCT04370262",Unknown,"medRxiv (https://doi.org/10.1101/2020.05.01.20086694), Gastroenterology (10.1053/j.gastro.2020.05.053)",,"FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Multiple global research sponsors
",Treatment,Other,Clinical,Unknown,"heparin; low molecular weight heparin (enoxaparin), anticoagulant
","NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.28.20046144), medRxiv (https://doi.org/10.1101/2020.04.15.20067017), medRxiv (https://doi.org/10.1101/2020.04.23.20076851), JACC (http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001?_ga=2.52741547.2046438614.1588863110-2104341714.1587686709), medRxiv (https://doi.org/10.1101/2020.05.27.20114694), J. Thrombosis and Thrombolysis (doi: 10.1007/s11239-020-02162-z), medRxiv (https://doi.org/10.1101/2020.06.22.20134957)",,"FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Pfizer; other global research sponsors,Treatment,Other,Clinical,Pfizer and other Phase II trial not yet recruiting July 2020,"Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor","NCT04332042, NCT04415151, NCT04390061, NCT04412252",Unknown,,,"FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Karyopharm Therapeutics,Treatment,Other,Clinical,Phase II trial ongoing July 2020,"Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound","NCT04355676, NCT04349098",Unknown,,Treat various cancers,"FDA-approved since 2019, approved to treat multiple myeloma",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
pHbarrier,Treatment,Other,Pre-clinical,Unknown,"pH barrier, transepithelial nebulized alkaline treatment",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2020
Washington University School of Medicine in St. Louis,Treatment,Other,Clinical,Phase II trial recruiting May 2020,"Luvox (fluvoxamine), a selective serotonin reuptake inhibitor",NCT04342663,Unknown,,,"FDA-approved since 1994, approved to treat obsessive compulsive disorder",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/14/2020
University of Hawaii (Boehringer Ingelheim),Treatment,Other,Clinical,Phase II not yet recruiting as of April 2020,Micardis (telmisartan),NCT04360551,Unknown,,,"FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2020
Insmed Inc.,Treatment,Other,Clinical,Phase II study to begin enrollment in May 2020,"brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)",EudraCT 2020-001643-13,Unknown,,Bronchiectasis and other inflammatory diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon) 
",Treatment,Other,Clinical,Unknown,"Novaferon, Nova, interferon, licensed in China for Hepatitis B","ChiCTR2000029573       

ChiCTR2000029496",Unknown,medRxiv (https://doi.org/10.1101/2020.04.24.20077735),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
"RedHill Biopharma/ NIAID
",Treatment,Other,Clinical,Unknown,"RHB-107 (upamostat, WX-671), serine protease inhibitor",,Unknown,,"Various oncology indications
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio ,Treatment,Other,Clinical,"Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020","UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide","NCT04345419, NCT04399356, NCT04436458",Unknown,,Atopic Dermatitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
University of Alabama at Birmingham,Treatment,Other,Clinical,Phase II not yet recruiting May 2020,"Lysteda/Cyklokapron (tranexamic acid), an antifibrinolytic","NCT04338074

NCT04338126",Unknown,,,"FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
Pulmotect,Treatment,Other,Clinical,Phase II trials recruiting July 2020,PUL-042 inhalation solution,"NCT04312997, NCT04313023",Unknown,,Prevent and treat respiratory complications in immunosuppressed cancer patients,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Abivax,Treatment,Other,Clinical,"Phase IIb/III trial started July 2020, top line results expected in 2020",ABX464 ,NCT04393038,Bpifrance,,"Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Exvastat Ltd / Global sponsors,Treatment,Other,Clinical,Phase II and Phase III trials recruiting July 2020,"Gleevac (imatinib), kinase inhibitor","NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416",Innovative Medicines Initiative,,,"FDA-approved since 2001, approved to treat various cancers",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Faron Pharmaceuticals / REMAP-CAP global trial / WHO SOLIDARITY trial/ various global researchers,Treatment,Other,Clinical,Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020 ,Traumakine (interferon beta 1-a),"NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948",Unknown,medRxiv (https://doi.org/10.1101/2020.05.28.20116467),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Noxopharm,Treatment,Other,Clinical,Phase I to begin in June 2020,Veyonda (idronoxil),,Unknown,,Prostate cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust,Treatment,Other,Clinical,Phase III study started in April 2020 (AstraZeneca),"Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor","NCT04350593, NCT04393246",Unknown,,Heart failure; Chronic kidney disease,"FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
The First Affiliated Hospital of Fujian Medical University/Novartis,Treatment,Other,Clinical,Phase II trial recruiting May 2020,"Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator",NCT04280588,Unknown,,,"FDA-approved since 2010, approved to treat multiple sclerosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
BioIncept,Treatment,Other,Pre-clinical,Preparing for a Phase I/IIa trial in May 2020,"sPIF (synthetic pre implantation factor)
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2020
Synairgen / University of Southampton,Treatment,Other,Clinical,Phase II began in March 2020; Initial results expected by end of June 2020,"SNG001, inhaled formulation of interferon beta-1a",NCT04385095,Unknown,,Asthma patients with cold or flu infection; COPD patients with viral infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.,Treatment,Other,Clinical,RECOVERY trial results released (dexamethasone) June 2020,Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids,"NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650",UK Government (University of Oxford RECOVERY trial),"medRxiv (https://doi.org/10.1101/2020.03.06.20032342), medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.07.20056390), medRxiv (https://doi.org/10.1101/2020.04.17.20064469), medRxiv (https://doi.org/10.1101/2020.04.17.20069773), medRxiv (https://doi.org/10.1101/2020.04.21.20066258), medRxiv (https://doi.org/10.1101/2020.05.04.20074609), medRxiv (https://doi.org/10.1101/2020.05.08.20094755), medRxiv (https://doi.org/10.1101/2020.05.11.20097709), medRxiv (https://doi.org/10.1101/2020.05.22.20110544), (http://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.17.20133579), medRxiv (https://doi.org/10.1101/2020.06.17.20134031), medRxiv (https://doi.org/10.1101/2020.06.19.20135491), medRxiv (https://doi.org/10.1101/2020.06.22.201372730), medRxiv (https://doi.org/10.1101/2020.06.23.20137471), medRxiv (https://doi.org/10.1101/2020.06.19.20109173), medRxiv (https://doi.org/10.1101/2020.06.22.20137273), medRxiv (https://doi.org/10.1101/2020.06.22.20134957), medRxiv (https://doi.org/10.1101/2020.06.22.20133413)",,"FDA-approved since at least the 1950s, approved to treat many diseases, including anti-iflammatory conditions and some cancers; asthma (ciclesconide)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly),Treatment,Other,Clinical,Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020,"Olumiant (baricitinib), Janus kinase (JAK) inhibitor","NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764",Unknown,medRxiv (https://doi.org/10.1101/2020.06.26.20135319),,"FDA-approved since 2018, approved to treat rheumatoid arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Numerous research sponsors globally,Treatment,Other,Clinical,Phase II recruiting July 2020; Individual patient expanded access ,"dipyridamole (Persantine), anticoagulant","NCT04424901, NCT04391179, NCT04410328",Unknown,"medRxiv (https://doi.org/10.1101/2020.02.27.20027557), Acta Pharm Sin B (https://doi.org/10.1016/j.apsb.2020.04.008)",,"FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Applied Therapeutics / numerous New York City hospitals,Treatment,Other,Clinical,Phase II recruiting July 2020; Individual patient expanded access,"AT-001, aldose reductase inhibitor",NCT04365699,Unknown,,Diabetic cardiomyopathy,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Amarin
  Corp",Treatment,Other,Clinical,Unknown,"Vascepa (icosapent ethyl), a form of eicosapentaenoic acid",NCT04412018,Unknown,,,"FDA approved since 2012, approved to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina, and reduce triglyceride levels in patients with severe hypertriglyceridemia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
"Orpheris
  (Ashvattha Therapeutics)",Treatment,Other,Clinical,FDA agreed to Phase II June 2020,"OP-101, dendrimer-based therapy",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Resverlogix,Treatment,Other,Clinical,Unknown,"apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor",,Unknown,,Treat various conditions ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
King's College London,Treatment,Other,Clinical,Phase IV trial recruiting in June 2020,Flarin (lipid ibuprofen),NCT04334629,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
"Various researchers globally, including University of Oxford",Treatment,Other,Clinical,Unknown,almitrine,"NCT04357457, NCT04380727",LifeArc (University of Oxford trial),,Various lung diseases including Acute Respiratory Distress Syndrome (ARDS),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
Vicore Pharma,Treatment,Other,Clinical,Unknown,"VP01, Angiotensin II Type 2 receptor activator ",,Life Arc ,,Pulmonary fibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
"Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/  Guangdong Uni-Innovation Pharmaceuticals Co., Ltd.",Treatment,Other,Clinical,Unknown,"leflunomide, pyrimidine synthesis inhibitor",NCT04361214,"Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)",medRxiv (https://doi.org/10.1101/2020.05.29.20114223) ,,"FDA-approved since 1998, approved to treat rheumatoid arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Various researchers worldwide, including University College London/ The Francis Crick  Institute (COVASE study)",Treatment,Other,Clinical,Phase III trials recruiting June 2020,"Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme","NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970",Life Arc (COVASE study),,,"FDA-approved since 1993, approved to treat cystic fibrosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
"Sun
  Pharmaceutical Industries Ltd",Treatment,Other,Clinical,"Phase II trial started June 2020, results expected by October","AQCH, plant-derived (phytopharmaeutical) drug",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Genentech,Treatment,Other,Clinical,Unknown,"MSTT1041A (anti-ST2, the receptor for IL-33)",,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Genentech,Treatment,Other,Clinical,Unknown,UTTR1147A (IL-22-Fc),,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
"Genetic Engineering and Biotechnology Center (CIGB), Cuba",Treatment,Other,Clinical,Unknown,"CIGB-258, immunoregulatory peptide",https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp,Ministry of Public Health of Cuba,medRxiv (https://doi.org/10.1101/2020.05.27.20110601),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"FSD
  Pharma",Treatment,Other,Clinical,Phase I topline results released June 2020,FSD-201 (ultramicronized palmitoylethanolamide),,,(https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase),Respiratory infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
PhaseBio,Treatment,Other,Clinical,Phase 2 trial expected to start dosing end of June 2020 and results in Q4 2020,"PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue",NCT04433546,,,Pulmonary arterial hypertension,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
PTC Therapeutics,Treatment,Other,Clinical,Phase 2/3 trial to start in June 2020,"PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)",,,,Various oncology indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
Dompe farmaceutici (as part of Exscalate4CoV),Treatment,Other,Clinical,Unknown,"raloxifene (Evista), an estrogen agonist/antagonist",,,,,"FDA approved since 1997, approved to treat osteoporosis and reduce risk of breat cancer in postmenopausal women with osteoporosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/22/2020
"Fulcrum
  Therapeutics",Treatment,Other,Clinical,Phase III trial to begin June 2020,"losmapimod, oral selective p38 mitogen activated protein kinase inhibitor",,,,"Multiple indications, including facioscapulohumeral muscular dystrophy ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
"Applied
  Biology/ Brown University/ Corpometria Institute",Treatment,Other,Clinical,Unknown,"dutasteride, anti-androgen",NCT04446429,,,,"FDA approved since 2001, approved to treat benign prostatic hyperplasia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
Merck KGaA,Treatment,Other,Pre-clinical,FDA cleared Phase II trial to begin in June 2020,"M5049, small molecule that block the activation of Toll-like receptor (TLR)7 and TLR8",,Unknown,,Various immuology indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Eisai,Treatment,Other,Clinical,Added to REMAP-COVID trial in June 2020,"Eritoran, TLR-4 antagonist",,,,Sepsis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/2/2020
Zydus Cadila/ Avant Sante Research Center,Treatment,Other,Clinical,Phase IIb trials approved to start in Mexico July 2020,"desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor",,Unknown,,Chronic Kidney Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
ViralClear Pharmaceuticals,Treatment,Other,Clinical,Phase II trial recruiting July 2020,"merimepodib, IMPDH inhibitor",NCT04410354,Unknown,,Chronic Hepatitis C; Psoriasis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Baxter,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 23, 2020",Oxiris Blood Purification Filter,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Bellerophon,Treatment,Device,Clinical,Individual patient expanded access,INOpulse,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ExThera Medical,Treatment,Device,Clinical,"DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020","Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction",,US Department of Defense (DOD),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
CytoSorbents Corporation,Treatment,Device,Clinical,"Individual patient expanded access; FDA issued an Emergency Use Authorization on April 10, 2020","CytoSorb (blood purification device, extracorporeal cytokine adsorber))",NCT04324528 ChiCTR2000030475 NCT04344080 DRKS00021447 NCT04385771,Unknown,medRxiv (https://doi.org/10.1101/2020.06.28.20133561),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
ALung Technologies,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 24, 2020",Hemolung Respiratory Assist System,,Unknown,,Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Terumo BCT Inc / Marker Therapeutics AG,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 9, 2020",Extracorporeal blood purification (EBP) devices,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Fresenius Medical,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 30, 2020","MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
Abiomed,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on May 29, 2020",Impella RP heart pump,,Unknown,,,"FDA-approved since 2017, approved to treat advanced heart failure",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
Scancell/ University of Nottingham/ Nottingham Trent University,Vaccine,DNA-based,Pre-clinical,Phase I to start in Q1 2021,DNA plasmid vaccine RBD&N,,Unknown,,Same platform as vaccine candidates for cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Entos Pharmaceuticals/ Cytiva,Vaccine,DNA-based,Pre-clinical,Phase I/II to start in late July 2020 ,DNA; Covigenix,,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
BioNet Asia,Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/20/2020
Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices,Vaccine,DNA-based,Phase I,"Phase I initial data released June 30, 2020; Phase II/III trials start July/August 2020 ",DNA plasmid vaccine with electroporation; INO-4800,"NCT04336410, NCT04447781",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx),Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/6/2020
Mediphage Bioceuticals/ University of Waterloo,Vaccine,DNA-based,Pre-clinical,Unknown,msDNA vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Symvivo,Vaccine,DNA-based,Pre-clinical,Unknown,"bacTRL-Spike
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Takis/ Applied DNA Sciences/ Evvivax,Vaccine,DNA-based,Pre-clinical,Animal results released in May 2020; Phase I to start in fall 2020,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Immunomic Therapeutics / EpiVax / PharmaJet,Vaccine,DNA-based,Pre-clinical,Unknown,"DNA plasmid, needle-free delivery",,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Zydus Cadila Healthcare Limited ,Vaccine,DNA-based,Pre-clinical,Phase I/II to start in July 2020 ,DNA plasmid,CTRI/2020/07/026352,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
OPENCORONA - Cobra Biologics / Karolinska Institute,Vaccine,DNA-based,Pre-clinical,Phase I to start in 2020,DNA with electroporation,,European Commission (Horizon 2020 Program),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Osaka University/ AnGes/ Takara Bio/ Cytiva,Vaccine,DNA-based,Pre-clinical,Phase I to start in July 2020,DNA plasmid,JapicCTI-205328,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex",Vaccine,DNA-based,Phase I,Phase I to start in July 2020,DNA vaccine (GX-19),NCT04445389,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
Chula Vaccine Research Center,Vaccine,DNA-based,Pre-clinical,Unknown,DNA with electroporation,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"National
  Research Centre, Egypt",Vaccine,DNA-based,Pre-clinical,Unknown,"DNA plasmid vaccine S, S1, S2, RBD & N",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Ege University,Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Valneva/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,"Inactivated (Inactivated + CpG 1018), VLA2001",,Unknown,,Same platform as vaccine candidates for Japanese Encephalitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Beijing Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase II,"In Phase II, June 2020",Inactivated,ChiCTR2000032459,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Wuhan Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase II,Phase III trial approved to start in United Arab Emirates June 2020; Early Phase I/II trial results released June 2020,Inactivated, ChiCTR2000031809,Unknown,(https://www.cnbg.com.cn/content/details_12_5545.html),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/25/2020
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Vaccine,Inactivated virus,Phase II,Phase II began June 2020,Inactivated,NCT04412538,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Sinovac/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated (inactivated + CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Osaka University / BIKEN / NIBIOHN,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sinovac/ Instituto Butantan,Vaccine,Inactivated virus,Phase II,Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020,Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc),"NCT04456595, NCT04352608, NCT04383574",Unknown,(http://www.sinovac.com/?optionid=754&auto_id=904),Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Beijing Minhai Biotechnology Co., Ltd.",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
"National Research Centre, Egypt",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated whole virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
KM Biologics,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated (inactivated + alum),,Unknown,,"Same platform as vaccine candidates for JE, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Selcuk University,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Indian Immunologicals Ltd/ Griffith University,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Codagenix / Serum Institute of India,Vaccine,Live attenuated virus,Pre-clinical,Animal data in summer 2020,Codon deoptimized live attenuated virus,,Unknown,,"Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Meissa Vaccines ,Vaccine,Live attenuated virus,Pre-clinical,Start Phase 1 beginning of 2021,MV-014-210,,Unknown,,Same platform as vaccine candidates for RSV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/2/2020
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
University of Manitoba,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; dendritic cell-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/20/2020
Greffex,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; Ad5 S (GREVAX™ platform),,Unknown,,"Same platform as vaccine candidates for MERS
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ReiThera/ Leukocare/ Univercells,Vaccine,Non-replicating viral vector,Pre-clinical,Start Phase I in summer 2020,Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Stabilitech Biopharma Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Oral Ad5 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Bharat Biotech/ Thomas Jefferson University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Recombinant deactivated rabies virus containing S1,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
GeoVax / BravoVax,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; MVA encoded VLP,,Unknown,,"Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council ,Vaccine,Non-replicating viral vector,Phase II,"Approved for military use in China on June 25, 2020; Phase II started April 2020; initial results released May 2020",Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV),NCT04313127 ChiCTR2000030906 ChiCTR2000031781 NCT04398147,Unknown,The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext),Same platform as vaccine candidates for EBOV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Altimmune / University of Alabama at Birmingham,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I trial to begin Q3 2020,"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
DZIF - German Center for Infection Research/ IDT Biologika GmbH,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; MVA-S encoded,,Unknown,,Same platform as vaccine candidates for many pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
ImmunityBio/ NantKwest,Vaccine,Non-replicating viral vector,Pre-clinical,Start Phase I in June 2020; vaccine to be included in US Operation Warp Speed trials according to company,"Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid",,Unknown,,"Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Valo Therapeutics Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based + HLA-matched peptides (Pan-Corona),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,"Non-replicating viral vector, MVA expressing structural proteins",,Unknown,,"Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent,Vaccine,Non-replicating viral vector,Pre-clinical,Will join US Operation Warp Speed vaccine trials in September 2020; Start Phase I/IIa July 2020,"Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Ebola, HIV, RSV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2020
Vaxart / Emergent BioSolutions,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I trial to begin in the second half of 2020,"Non-replicating viral vector; Oral Vaccine
 platform",,Unknown,,"Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Georgia/ University of Iowa,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,,Unknown,,Same platform as vaccine candidates for MERS ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca ",Vaccine,Non-replicating viral vector,Phase III,Phase III enrolling in Brazil end of June 2020; South African trial starts end of June 2020; Will join US Operation Warp Speed Phase III vaccine trials in August 2020; Phase II/III trials enrolling May 2020,Non-replicating viral vector; AZD 1222 (formerly ChAdOx1),"ISRCTN89951424, NCT04324606, EudraCT 2020-001072-15, EudraCT 2020-001228-32, NCT04400838, ISRCTN89951424, PACTR202006922165132","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance",,"Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/6/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,MVA-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Vaccine,Non-replicating viral vector,Pre-clinical,Phase 1 to begin second half of 2020,"AAVCOVID, Adeno-associated viral vector (AAV), spike protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Gamaleya  Research Institute,Vaccine,Non-replicating viral vector,Phase I,Unknown,Adeno-based,NCT04437875,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
"National
  Research Centre, Egypt",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Influenza A H1N1 vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
ID Pharma,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Sendai virus vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Ankara University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit (gp-96 backbone),,Unknown,,"Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Sanofi Pasteur / GSK,Vaccine,Protein subunit,Pre-clinical,Phase I/II to start in September 2020,"Protein subunit; S protein, baculovirus production",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
iBio / CC-Pharming,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit; Subunit protein, plant produced",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ImmunoPrecise/ LiteVax BV,Vaccine,Protein subunit,Pre-clinical,Unknown,Spike-based (epitope screening),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics,Vaccine,Protein subunit,Phase I,"Will join US Operation Warp Speed vaccine trials, Phase III trial to start in fall 2020; Phase I/II started May 2020; top-line data expected July 2020",Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373),NCT04368988,Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense,,"Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma,Vaccine,Protein subunit,Phase I,Phase I trial started July 2020,Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19),NCT04453852,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"National Institute of Infectious Disease, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, S protein + adjuvant",,Unknown,,Same platform as vaccine candidates for Influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ExpreS2ion,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, drosophila S2 insect cell expression system VLPs",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"LakePharma, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, nanoparticle vaccine",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Axon Neuroscience SE,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptides derived from Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Vaccine,Protein subunit,Pre-clinical,Unknown,S-2 P protein + CpG 1018,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Baylor College of Medicine,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S1 or RBD protein,,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Innovax / Xiamen University / GSK,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; COVID-19 XWG-03 truncated Spike proteins,,Unknown,,"Same platform as vaccine candidates for HPV  
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Quadram Institute Biosciences,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,"Same platform as vaccine candidates for Flu A, plaque
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Vaccine,Protein subunit,Pre-clinical,Received approval to launch clinical trials in China in June 2020,Adjuvanted recombinant protein (RBD-Dimer),NCT04445194,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Yisheng Biopharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"University of California, San Diego",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch,,National Science Foundation (Rapid Response Research [RAPID] grant),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
AJ Vaccines,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"VIDO-InterVac, University of Saskatchewan",Vaccine,Protein subunit,Pre-clinical,Animal testing results expected in April 2020,"Protein subunit, adjuvanted microsphere peptide",,The Government of Saskatchewan and the Canadian Federal Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
MIGAL Galilee Research Institute,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; oral E. coli-based protein expression system of S and N proteins,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Biological E Ltd,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; adjuvanted protein subunit (RBD),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
OncoGen,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Cambridge / DIOSynVax,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,Protein subunit; S protein,,Unknown,,"Influenza, Ebola",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; peptide vaccine,,Unknown,,Same platform as vaccine candidates for Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Applied Biotechnology Institute, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Orally delivered, heat stable subunit",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
University of Alberta,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; spike based,,Unknown,,Same platform as vaccine candidates for Hepatitis C,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
St. Petersburg Scientific Research Institute of Vaccines and Serums,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic",Vaccine,Protein subunit,Pre-clinical,Phase I to begin by February 2021,"Protein subunit, capsid-like particle (CLP)",,European Commission (Horizon 2020 Program),,Same platform as vaccine candidates for HPV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/14/2020
Clover Biopharmaceuticals Inc./ GSK/ Dynavax,Vaccine,Protein subunit,Phase I,"Phase I trial started June 2020, preliminary results expected August 2020","Protein subunit, native like trimeric subunit spike protein",NCT04405908,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for HIV, RSV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
WRAIR / USAMRIID,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Flow Pharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, peptide",,Unknown,,"Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Neovii/Tel Aviv University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
EpiVax / University of Georgia,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,Same platform as vaccine candidates for Inf H7N9,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Generex / EpiVax,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; Ii-Key peptide,,Unknown,,"Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vaxil Bio,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
BiOMVis Srl/ University of Trento,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
University of Pittsburgh,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,"PittCoVacc, Protein subunit, microneedle arrays S1 subunit",,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, VLP-recombinant protein + adjuvant",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Queensland / GSK / Dynavax/ CSL,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; molecular clamp stabilized Spike protein,,Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation,,"Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
Vabiotech,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S protein in IC-BEVS  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
AnyGo Technology,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S1-Fc fusion protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; subunit vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
UMN Pharma (Shionogi),Vaccine,Protein subunit,Pre-clinical,Phase I to start by end of 2020,"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",,Japan Agency for Medical Research and Development,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Vaccine,Protein subunit,Pre-clinical,Start Phase I testing by summer 2020,"Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",,Unknown,,"Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
EpiVax ,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit EPV-CoV-19,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Lomonosov Moscow State University,Vaccine,Protein subunit,Pre-clinical,Unknown,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Kentucky BioProcessing (British American Tobacco),Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
"Chulalongkorn University/ GPO, Thailand",Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein fused with Fc of IgG + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
PDS Biotechnology,Vaccine,Protein subunit,Pre-clinical,Unknown,PDS-0203; Versamune T-cell activating technology ,,Unknown,,"Same platform as vaccines against cancers, HBV, influenza, and tuberculosis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
"Verndari/ University of California, Davis",Vaccine,Protein subunit,Pre-clinical,Phase I to start summer 2020,Spike protein; VaxiPatch microneedle array dermal patch,,Unknown,,Same platform as vaccines against influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,Protein subunit,Pre-clinical,Unknown,Targeted (Langerhans cell specific) protein subunit; spike based,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
"MOGAM Institute for Biomedical Research, GC Pharma",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
"University of San Martin and CONICET, Argentina",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Baiya Phytopharm/ Chula Vaccine Research Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Plant-based subunit (RBD-Fc + Adjuvant),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National
  Research Centre, Egypt",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein Subunit S, N, M & S1 protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
University of Virginia,Vaccine,Protein subunit,Pre-clinical,Unknown,S subunit intranasal liposomal formulation with GLA/3M052 adjs.,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Izmir Biomedicine and Genome Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Bogazici University,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptide + novel adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
InnoMedica,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, TaliCoVax19 ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Institut Pasteur / Themis / University of Pittsburgh / Merck,Vaccine,Replicating viral vector,Pre-clinical,Start animal testing in April 2020; clinical testing to start later in 2020,Replicating viral vector; measles vector,,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/28/2020
DZIF - German Center for Infection Research/ CanVirex AG,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Measles virus (S, N targets)",,Unknown,,"Same platform as vaccine candidates for Zika, H7N9, CHIKV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"The Lancaster University, UK",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Avian paramyxovirus vector (APMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
IAVI/ Merck,Vaccine,Replicating viral vector,Pre-clinical,Will join US Operation Warp Speed vaccine trials; clinical studies to start in 2020,"Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Zydus Cadila Healthcare Limited ,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
The University of Hong Kong,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, influenza vector expressing RBD",,Coalition for Epidemic Preparedness (CEPI),,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
KU Leuven,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; YF17D Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
BIOCAD / IEM,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Newcastle disease virus vector (NDV-SARS-CoV-2/Spike),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Vaccine,Replicating viral vector,Pre-clinical,Start Phase I trial in fall 2020,M2-deficient single replication (M2SR) influenza vector,,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Tonix Pharma / Southern Research,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; horsepox vector expressing S protein; TNX-1800,,Unknown,,"Same platform as vaccine candidates for smallpox, monkeypox",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
University of Western Ontario,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV-S,,Unknown,,"Same platform as vaccine candidates for HIV, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Fundacao Oswaldo Cruz and Instituto Buntantan,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Attenuated Influenza expressing an antigenic portion of the Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Vaccine,Replicating viral vector,Pre-clinical,Unknown,VSV-S ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Greenlight Biosciences
",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Moderna/ NIAID/ Lonza/ Catalent/ Rovi,Vaccine,RNA-based vaccine,Phase II,Will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020,RNA; LNP-encapsulated mRNA (mRNA 1273),"NCT04283461, NCT04405076",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine),Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
CanSino Biologics/Precision Nanosystems,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA lipid nanoparticle (mRNA-LNP),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
BIOCAD,Vaccine,RNA-based vaccine,Pre-clinical,Animal studies begin in April 2020,RNA; liposome-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for cancer   ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
GeneOne Life Science / Houston Methodist,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I early 2021,RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
China CDC / Tongji University / Stermina,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Tokyo / Daiichi-Sankyo,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Arcturus/Duke-NUS/ Catalent
",Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I trial August 2020,LUNAR-COV19; RNA; mRNA,,Unknown,,Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; Replicating defective SARS-CoV-2 derived RNAs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CureVac,Vaccine,RNA-based vaccine,Phase I,Start Phase I/IIa trial June 2020,RNA; mRNA,NCT04449276,Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB),,"Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Imperial College London/ VacEquity Global Health,Vaccine,RNA-based vaccine,Phase I,Phase I/II trial started June 2020,RNA; LNP-nCoVsaRNA,ISRCTN17072692,UK Government,,"Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sanofi Pasteur / Translate Bio,Vaccine,RNA-based vaccine,Pre-clinical,Phase I to start Q4 2020,"LNP-mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/24/2020
"RNAimmune, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; several mRNA candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
BioNTech/ Fosun Pharma/ Pfizer,Vaccine,RNA-based vaccine,Phase I,"Phase III trial may start as early as July 2020 (not participating in the NIH testing program); Phase I/II started April 2020; first data released July 1, 2020","3 LNP-mRNAs; BNT162 
","EudraCT 2020-001038-36, NCT04368728",Unknown,"Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Ziphius Therapeutics/ Ghent University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
Max Planck Institute of Colloids and Interfaces,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA in targeted LPNs (Langerhans cell specific),,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self amplifying RNA, self-assembling delivery system",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Chula Vaccine Research Center/University of Pennsylvania,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,LNP-mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,ChiCTR2000034112,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Selcuk University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Medicago Inc./ Université Laval,Vaccine,Virus-like particle,Pre-clinical,Start Phase I in July/August 2020; Phase II by the end of 2020,VLP; plant-derived VLP,NCT04450004,Unknown,,"Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"ARTES Biotechnology
",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; eVLP,,Unknown,,"Same platform as vaccine candidates for malaria
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
University of Sao Paulo,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs peptides/whole virus,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
VBI Vaccines / National Research Council of Canada,Vaccine,Virus-like particle,Pre-clinical,Start Phase I testing by end of 2020,"Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein",,Unknown,,"Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Saiba GmbH,Vaccine,Virus-like particle,Pre-clinical,Unknown,"VLP; virus-like particle, based on RBD displayed on virus-like particle",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Doherty Institute,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Imophoron Ltd / Bristol University's Max Planck Centre,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; ADDomerTM multiepitope display,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
OSIVAX,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (COVID-19 and SARS1),,European Innovation Council (EIC),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Navarrabiomed, Oncoimmunology group",Vaccine,Virus-like particle,Pre-clinical,Unknown,"Virus-like particles, lentivirus, and baculovirus vehicles",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Vaccine,Virus-like particle,Pre-clinical,Unknown,S protein integrated in HIV VLPs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Middle East Technical University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Medicago Inc./ Dynavax,Vaccine,Virus-like particle,Pre-clinical,Phase I to start mid-July 2020,VLP (CoVLP)+ Adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"Medicago
  Inc./ GSK",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (CoVLP)+ Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Tulane University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ISR Immune System Regulation,Vaccine,Unknown,Pre-clinical,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Shenzhen Geno-Immune Medical Institute,Vaccine,Unknown,Pre-clinical,Unknown,Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins,NCT04299724,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Covaxx,Vaccine,Unknown,Pre-clinical,Phase I to start in summer 2020,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Vaccine,Unknown,Pre-clinical,Animal study results by October 2020,"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",,Analog Devices Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
Shenzhen Geno-Immune Medical Institute,Vaccine,Unknown,Pre-clinical,Unknown,LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes,NCT04276896,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
SmartPharm Therapeutics / Sorrento Therapeutics,Vaccine,Unknown,Pre-clinical,Unknown,"Gene-encoded antibody vaccine, non-viral nanoparticle delivery",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vir Biotechnology / GSK,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
AbVision,Vaccine,Unknown,Pre-clinical,Unknown,AVI-205,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
SK Biosciences,Vaccine,Unknown,Pre-clinical,Phase I begins as early as September 2020,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Precision Vaccines Program at Boston Children's Hospital,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Oragenics (Noachis Terra)/ Aragen Bioscience
",Vaccine,Unknown,Pre-clinical,Start Phase I in late 2020 or early 2021,"TerraCoV2
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
Vivaldi Biosciences/ Esco Aster Pte Ltd,Vaccine,Unknown,Pre-clinical,Unknown,Chimeric vaccine (coronavirus and influenza),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Adeleke University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Codiak BioSciences/ Ragon Institute,Vaccine,Unknown,Pre-clinical,Unknown,exoVACC exome platform,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Vault Pharma/ University of California Los Angeles,Vaccine,Unknown,Pre-clinical,Unknown,nanoparticles (vaults) as second-line defense of infection,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
NidoVax,Vaccine,Unknown,Pre-clinical,Unknown,unknown; IMT504 technology,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"University of California, Los Angeles (Horwitz Lab)",Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens,,Unknown,,Same platform as vaccines against select agents and emerging pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
The First Affiliated Hospital of Guangzhou Medical University,Dormant / Discontinued,Dormant / Discontinued,Clinical,,Recombinant ACE2 (angiotensin-converting enzyme 2),NCT04287686 ,,Study stopped before recruitment,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
The Second Hospital of Nanjing Medical University,Dormant / Discontinued,Dormant / Discontinued,Clinical,,Washed microbiota transplantation,NCT04251767,,Study stopped before recruitment,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Mianyang Central Hospital 
",Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated March 30, 2020
","Combination of ebastine, lopinavir, and interferon alpha
",ChiCTR2000030535,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Numerous trials with Chinese research sponsors,Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials ","azvudine, reverse transcriptase inhibitor
","ChiCTR2000030487

ChiCTR2000030424

ChiCTR2000029853",,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
"Roche/the First Hospital Affiliated to Zhejiang University's Medical School
",Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated February 12, 2020 
","Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor
","ChiCTR2000029544

ChiCTR2000029548",,medRxiv (https://doi.org/10.1101/2020.04.29.20085761) (ChiCTR2000029544),,"FDA-approved since 2018, approved to treat influenza
",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020